1. Merrell Dow Pharmaceuticals (32 from 455 patents)

2. Merrell Pharmaceuticals, Inc. (15 from 194 patents)

3. Mannkind Corporation (7 from 278 patents)

4. Hoechst Marion Roussel (7 from 236 patents)

5. The University of Arizona (5 from 973 patents)

6. Aventis Pharmaceuticals Inc. (4 from 207 patents)

7. Aventis Pharma Deutschland, Gmbh (3 from 330 patents)

8. Tolero Pharmaceuticals, Inc. (3 from 21 patents)

9. The Translational Genomics Research Institute (2 from 119 patents)

10. Other (1 from 832,880 patents)

11. Sumitomo Dainippon Pharma Oncology, Inc. (1 from 11 patents)

12. Selectide Corporation (1 from 10 patents)

13. Pharmacyclics, Inc. (193 patents)

14. Aventis Pharma Limited (39 patents)

15. Sumitomo Pharma Oncology, Inc. (11 patents)

1. 10752594 - JAK1 and ALK2 inhibitors and methods for their use

2. 10202356 - JAK2 and ALK2 inhibitors and methods for their use

3. 9981901 - IRE-1α inhibitors

4. 9833455 - Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors

5. 9714247 - Multiple kinase pathway inhibitors

6. 9546149 - IRE-1α inhibitors

7. 9493454 - Multiple kinase pathway inhibitors

8. 9248131 - Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance

9. 9241942 - IRE-1α inhibitors

10. 9221805 - Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors

11. 8987309 - Compounds, pharmaceutical compositions and methods of use of 2-aryl pyridylazoles

12. 8835491 - Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance

13. 8614253 - IRE-1α inhibitors

14. 8604031 - Intracellular kinase inhibitors

15. 8394742 - Methods, compounds and compositions with genotype selective anticancer activity